Tawa Marianne, Kopp Erin, McCann Sue, Cantrell Wendy
Dana Farber Cancer Institute.
City of Hope Comprehensive Cancer Center.
Clin J Oncol Nurs. 2019 Aug 1;23(4):E73-E80. doi: 10.1188/19.CJON.E73-E80.
Cutaneous T-cell lymphoma (CTCL), including subtypes mycosis fungoides (MF) and Sézary syndrome (SS), represents a rare group of non-Hodgkin lymphomas. Mogamulizumab is a first-in-class monoclonal antibody that selectively binds to C-C chemokine receptor 4, which is overexpressed on the surface of tumor cells in T-cell malignancies, including MF/SS-type CTCL.
This review identifies common diagnostic features of MF/SS, the efficacy and side effect profile of mogamulizumab, and practical management strategies for optimizing the nursing care of patients with MF/SS-type CTCL.
Case studies are used to describe the role of mogamulizumab in CTCL and to review practical considerations when administering mogamulizumab to patients.
Mogamulizumab is an effective treatment for adult patients with relapsed or refractory MF/SS-type CTCL who have received at least one prior systemic therapy. Infusion reactions and drug eruptions require prompt diagnosis and treatment.
皮肤T细胞淋巴瘤（CTCL），包括蕈样肉芽肿（MF）和塞扎里综合征（SS）亚型，是一组罕见的非霍奇金淋巴瘤。莫加莫单抗是首个选择性结合C-C趋化因子受体4的单克隆抗体，该受体在包括MF/SS型CTCL在内的T细胞恶性肿瘤的肿瘤细胞表面过度表达。
本综述确定MF/SS的常见诊断特征、莫加莫单抗的疗效和副作用概况，以及优化MF/SS型CTCL患者护理的实际管理策略。
通过病例研究描述莫加莫单抗在CTCL中的作用，并回顾给患者使用莫加莫单抗时的实际注意事项。
莫加莫单抗对接受过至少一种先前全身治疗的复发或难治性MF/SS型CTCL成年患者是一种有效的治疗方法。输液反应和药物疹需要及时诊断和治疗。
